90055-68-8

Usage

Uses

Used in Pharmaceutical Industry:
(+/-)-methyl-(2-chlorophenyl)-(4,5,6,7-4H-thieno[3,2,-c]pyrid-5-yl) acetamide is used as a potential pharmaceutical candidate for the development of new drugs. Its complex structure and the presence of the thieno[3,2,-c]pyrid-5-yl group suggest that it may have biological activity, making it a promising compound for further research and development in the pharmaceutical field.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (+/-)-methyl-(2-chlorophenyl)-(4,5,6,7-4H-thieno[3,2,-c]pyrid-5-yl) acetamide is used for studying its potential interactions with biological targets. (+/-)-methyl-(2-chlorophenyl)-(4,5,6,7-4H-thieno[3,2,-c]pyrid-5-yl) acetamide's unique structure may allow it to bind to specific receptors or enzymes, which could lead to the discovery of new therapeutic agents or a better understanding of biological processes.

Upstream product

• 444891-19-4 2-bromo-2-(2-chlorophenyl)acetonitrile 
• 2856-63-5 2-Chlorophenylacetonitrile 
• 444728-11-4 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)acetonitrile 

Downstream Products

• 444728-14-7 (+)-(1S)-camphor-10-sulfonic acid salt of (S)-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetamide 
• 120202-72-4 methyl (R)-(-)-(2-chlorophenyl)-(6,7dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrochloride 
• 113665-84-2 (S)-(+)-clopidogrel 
• 120202-66-6 (S)-(+)-clopidogrel bisulfate 
• 90055-48-4 clopidogrel 
• 90055-55-3 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)acetic acid 
• 929200-19-1 sodium (+/-)-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-acetate 

Relevant academic research and scientific papers

Synthetic improvements in the preparation of clopidogrel

Synthetic improvements in the preparation of clopidogrel are described. The synthesis was accomplished in four steps or one-pot in above 70% overall yield. The process featured PTC catalyzed alkaline hydrolysis of the key intermediate 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetonitrile and highly effective kinetic resolution of racemic clopidogrel using L-camphorsulphonic acid in toluene and has been successfully used in a 50-kg pilot test.

NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL

The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for such forms and compositions. The pharmaceutical compositions may be used, in particular, for inhibiting platelet aggregation or for treating, preventing or managing thrombosis, atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial infarction, non-Q-wave myocardial infarction, atherosclerosis, peripheral arterial disease, or unstable angina. The present invention also relates to methods of treating said disorders. Formula (1).